Profil
Marc Dechamps is Chief Executive Officer at Bioxodes SA since 2022.
Mr. Dechamps is Independent Director at OSE Immunotherapeutics SA since 2024.
Formerly, Mr. Dechamps was Co-Managing Director at Catalent Gosselies PS SA. Mr. Dechamps was Director & Head-Business Development at eTheRNA immunotherapies NV.
Postes actifs de Marc Dechamps
| Sociétés | Poste | Début |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Directeur/Membre du Conseil | 19/06/2024 |
Bioxodes SA
Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation | Directeur Général | 01/10/2022 |
Anciens postes connus de Marc Dechamps
| Sociétés | Poste | Fin |
|---|---|---|
Delphi Genetics SA
Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions | Directeur Général | 01/07/2017 |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Develops novel immunotherapies to overcome cancers and infectious diseases | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Delphi Genetics SA
Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions | Health Technology |
Bioxodes SA
Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation | Health Technology |
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Develops novel immunotherapies to overcome cancers and infectious diseases | Health Technology |
















